Literature DB >> 7034642

Amoxicillin-clavulanic acid in treatment of urinary tract infection due to gram-negative bacteria resistant to penicillin.

R Martinelli, A A Lopes, M M de Oliveira, H Rocha.   

Abstract

Twenty-two adult patients with urinary tract infections caused by penicillin-resistant bacteria completed treatment with amoxicillin alone or amoxicillin plus clavulanic acid in a randomized double-blind clinical trial. Of the 13 patients treated with amoxicillin plus clavulanic acid, the absence of bacteriuria within 7 days of therapy was observed in 85%, as compared with only 25% of the 8 patients receiving amoxicillin only. There were no significant side effects nor any clinical, biochemical, or hematological abnormalities related to either treatment. It was concluded that the combination of clavulanic acid and amoxicillin could be useful in the treatment of uncomplicated urinary tract infection caused by penicillin-resistant bacteria.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7034642      PMCID： PMC181801          DOI： 10.1128/AAC.20.6.800

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  In vitro study of clavulanic acid in combination with penicillin, amoxycillin, and carbenicillin.

Authors:  R Wise; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

2.  THE LOCALIZATION AND TREATMENT OF URINARY TRACT INFECTIONS: THE ROLE OF BACTERICIDAL URINE LEVELS AS OPPOSED TO SERUM LEVELS.

Authors:  T A STAMEY; D E GOVAN; J M PALMER
Journal:  Medicine (Baltimore)       Date:  1965-01       Impact factor: 1.889

3.  Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus.

Authors:  C Reading; M Cole
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

4.  Relapse and reinfection in chronic bacteriuria. II. The correlation between site of infection and pattern of recurrence in chronic bacteriuria.

Authors:  M Turck; A R Ronald; R G Petersdorf
Journal:  N Engl J Med       Date:  1968-02-22       Impact factor: 91.245

5.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

6.  Combined activitiy of clavulanic acid and ticarcillin against ticarcillin-resistant, gram-negative bacilli.

Authors:  J W Paisley; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1978-08       Impact factor: 5.191

7.  In vitro synergistic properties of clavulanic acid, with ampicillin, amoxycillin and ticarcillin.

Authors:  P A Hunter; K Coleman; J Fisher; D Taylor
Journal:  J Antimicrob Chemother       Date:  1980-07       Impact factor: 5.790

8.  The inhibition of staphylococcal beta-lactamase by clavulanic acid.

Authors:  C Reading; P Hepburn
Journal:  Biochem J       Date:  1979-04-01       Impact factor: 3.857

9.  Sodium clavulanate potentiation of cephalosporin activity against clinical isolates of cephalothin-resistant Klebsiella pneumoniae.

Authors:  R T Jackson; L F Harris; R H Alford
Journal:  Antimicrob Agents Chemother       Date:  1978-07       Impact factor: 5.191

10.  [Kinetics of beta-lactamase inhibition by clavulanic acid].

Authors:  R Labia; J Peduzzi
Journal:  Biochim Biophys Acta       Date:  1978-10-12
  10 in total
  11 in total

1.  Switching from CLSI to EUCAST XL susceptibility breakpoint: its implication in urinary tract infection in men.

Authors:  Amaia Aguirre-Quiñonero; M C Lecaroz Agara; A Canut Blasco
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-06-23       Impact factor: 3.267

2.  Five-year survey of changing patterns of susceptibility of bacterial uropathogens to trimethoprim-sulfamethoxazole and other antimicrobial agents.

Authors:  U Alon; G Davidai; M Berant; D Merzbach
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

3.  Activities of amoxicillin and clavulanic acid combinations against urinary tract infections.

Authors:  F Crokaert; M P van der Linden; E Yourassowsky
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

4.  Augmentin (amoxycillin-clavulanic acid) compared with co-trimoxazole in urinary tract infections.

Authors:  G J Fancourt; S G Matts; C J Mitchell
Journal:  Br Med J (Clin Res Ed)       Date:  1984-07-14

5.  Amoxicillin-clavulanic acid versus cefaclor in the treatment of urinary tract infections and their effects on the urogenital and rectal flora.

Authors:  A Iravani; G A Richard
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

6.  Comparative study of amoxicillin-clavulanic acid and cephalexin in the treatment of bacteriuria during pregnancy.

Authors:  S J Pedler; A J Bint
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

7.  In vitro evaluation of Augmentin by broth microdilution and disk diffusion susceptibility testing: regression analysis, tentative interpretive criteria, and quality control limits.

Authors:  P C Fuchs; A L Barry; C Thornsberry; T L Gavan; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

8.  Prospective comparison of amoxicillin-clavulanic acid and cefaclor in treatment of uncomplicated urinary tract infections.

Authors:  M J Gurwith; G E Stein; D Gurwith
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

9.  Augmentation of the in vitro activity of azlocillin against Bacteroides fragilis by clavulanic acid.

Authors:  M B Bansal; S K Chuah; H Thadepalli
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

10.  Clinical trial of the efficacy and safety of ticarcillin and clavulanic acid.

Authors:  G A Roselle; R Bode; B Hamilton; M Bibler; R Sullivan; R Douce; J L Staneck; W E Bullock
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.